Romosozumab plus alendronate led to a greater improvement in bone strength than alendronate alone in postmenopausal women ...

Trabecular meshwork (TM) tissue is subjected to constant mechanical stress due to the ocular pulse created by the cardiac cycle. This brings about alterations in the membrane lipids and associated ...

Arkadidy Yadgarov, of OMNI Eye Services in Atlanta, GA and the first surgeon in the country to utilize the advanced technology adds “There are a lot of trabecular technologies, but this is an ...

Iantrek has reached an exciting milestone as we transition from development of our bio-interventional technologies to ...

Treatment with romosozumab led to improvements in bone microarchitecture among postmenopausal women with osteoporosis.

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Patients with glaucoma who are using prostaglandin F (FP) receptor agonists to control their disease may experience ...

S.A., a global leader in AI-driven bone microarchitecture imaging solutions, proudly announces 510(k) clearance from FDA and ...

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

We believe that alcohol consumption, cardiac disease, brain infarction and trabecular hematoma are independent risk factors for seizures. The use of urokinase is a protective factor against seizures.

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).